Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Guggenheim from $33.00 to $42.00. They now have a "buy" rating on the stock.
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 [Yahoo! Finance]
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
EXEL vs. INCY: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]